Synergia Medical

Synergia Medical is a private, clinical-stage medical device company pioneering an optoelectronic neuromodulation platform. Its lead product, NAO.VNS™, is a Vagus Nerve Stimulation (VNS) device for drug-resistant epilepsy, which has successfully completed initial safety evaluations in a first-in-human study (AURORA) with five patients implanted. The company's technology promises full MRI compatibility, electromagnetic interference (EMI) immunity, extended battery life, and enhanced cybersecurity, positioning it to address significant unmet needs in the neuromodulation market. Backed by regional and European Union funding, Synergia is preparing for pivotal trials to seek FDA and CE Mark approvals.

Optoelectronic neuromodulation platform that replaces metal leads and conductors with biocompatible materials (e.g., quartz, polymer optical fibers) to deliver stimulation via light, aiming for full MRI compatibility, EMI immunity, extended battery life, and enhanced cybersecurity.

Synergia competes in the Vagus Nerve Stimulation (VNS) market, dominated by established players like LivaNova. Its competition is not based on price but on a disruptive technological value proposition: offering full MRI compatibility and EMI immunity where current devices have significant limitations. It also faces potential future competition from other next-generation neurostimulation approaches, such as closed-loop systems.